In this episode of Science Lab, we break down the latest research comparing traditional cigarette smoking with heated tobacco products (HTPs). Using evidence from multiple clinical studies, she explains how switching completely from smoking to HTPs affects biomarkers of exposure, biomarkers of potential harm, reported symptoms, and overall risk profiles.
All content for GFN News is the property of GFN.TV and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode of Science Lab, we break down the latest research comparing traditional cigarette smoking with heated tobacco products (HTPs). Using evidence from multiple clinical studies, she explains how switching completely from smoking to HTPs affects biomarkers of exposure, biomarkers of potential harm, reported symptoms, and overall risk profiles.
GFN.TV Interviews | TOBACCO SCORECARD | Real Progress Tobacco Control Fails to Admit
GFN News
33 minutes 8 seconds
5 days ago
GFN.TV Interviews | TOBACCO SCORECARD | Real Progress Tobacco Control Fails to Admit
Former Iowa Attorney General Tom Miller—America’s longest-serving AG and a principal architect of the Master Settlement Agreement—joins GFN.TV with a clear warning: the U.S. is making extraordinary progress against combustible tobacco, yet the public isn’t hearing about it. Smoking has collapsed to historic lows, youth vaping has fallen 70% since 2019, and millions of adults have shifted to far safer non-combustible nicotine products. By any honest measure, it’s one of the most significant public-health successes in decades. So why isn’t tobacco control talking about it?
Featuring:
TOM MILLER
Former Iowa Attorney General
Founder, Miller Monitoring and Consulting, LLC.
GFN News
In this episode of Science Lab, we break down the latest research comparing traditional cigarette smoking with heated tobacco products (HTPs). Using evidence from multiple clinical studies, she explains how switching completely from smoking to HTPs affects biomarkers of exposure, biomarkers of potential harm, reported symptoms, and overall risk profiles.
